Serum thymidine kinase in hematologic malignancies

R. Luoni, G. Ucci, A. Riccardi, P. Spriano, M. Danova, E. Cassano, E. Molinari, E. Ascari

Research output: Contribution to journalArticlepeer-review


In a prospective study, serum thymidine kinase (S-TK) levels were determined in 135 consecutive patients with different hematological malignancies (chronic myeloid leukemia, CML: 4 pts; acute leukemias, AL: 32 pts; myelodysplastic syndromes, MDS: 10 pts; multiple myeloma, MM: 52 pts; Waldenstrom's macroglobulinemia, WM: 3 pts; monoclonal gammopathies of undetermined significance, MGUS: 32 pts; hairy cell leukemia, HCL; 2 pts). Our normal levels for S-TK were below 5.2 U/μl. The highest S-TK values (4-149.8 U/μl) were found in AL at presentation and in CML. The S-TK values were lower in MDS than in AL (p

Original languageEnglish
Pages (from-to)31-35
Number of pages5
Issue number1
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Serum thymidine kinase in hematologic malignancies'. Together they form a unique fingerprint.

Cite this